Introduction
============

Hepatitis C virus (HCV) is a highly diverse human pathogen that is prevalent worldwide. The virus has been classified into seven distinct genotypes, which are approximately 30% divergent at the nucleotide sequence level \[[@b1]\]. The genotypes segregate according to geographical distribution, with certain genotypes widely distributed across the globe. In the UK, genotypes 1 and 3 (gt1 and gt3, respectively) predominate and have approximately equivalent prevalence \[[@b2],[@b3]\]. From a clinical point of view, the distribution of HCV genotypes is of great importance due to the distinctive clinical outcomes associated with gt1 or gt3 infection.

The response to antiviral therapies is influenced by HCV genotype. Gt1 infections have a lower sustained virological response (SVR) rate when treated with combination pegylated interferon (IFN)*α* and ribavirin (40--50% compared to 70--80% for gt3) \[[@b4],[@b5]\]. This effect of HCV genotype on treatment outcome differs depending on the specific antiviral drugs employed. A recent phase III clinical trial of the pan-genotypic direct acting antiviral sofosbuvir identified a higher rate of relapse in gt3-infected patients, suggesting that gt3 HCV may be relatively more difficult to treat when using IFN-free regimes \[[@b6]\]. HCV also exerts genotype-specific effects on host cell lipid metabolism. Gt3 infections are associated with an increased prevalence of liver steatosis and reduced serum cholesterol concentration, both of which resolve following successful viral clearance \[[@b7]--[@b10]\]. These genotype-specific clinical manifestations are independent of known negative predictors of treatment response \[[@b5]\] and co-morbidities associated with liver steatosis \[[@b10]\].

The genotype-specific decrease in peripheral serum cholesterol levels provides a potential mechanism through which HCV could modulate peripheral immune cells in a genotype-specific manner during chronic infection. Peripheral cholesterol levels are known to play an important role in regulating proinflammatory immune responses within immune cells \[[@b11],[@b12]\]. This raises the possibility that gt3 HCV, by reducing peripheral cholesterol levels, also reduces the proinflammatory effects exerted by peripheral immune cells. Studies investigating the interaction between chronic HCV infection and peripheral blood immune cells have identified a proinflammatory signature associated with elevated interferon-stimulated genes (ISGs) \[[@b13]\], as well as elevated expression of proinflammatory cytokines \[[@b14]\]. However, these studies have focussed exclusively on infection with gt1 HCV and fail to address potential genotype-specific peripheral blood mononuclear cell (PBMC) responses. In this study, we set out to explore distinctive transcriptional profiles induced by different HCV genotypes in PBMCs.

Materials and Methods
=====================

Clinical samples
----------------

Clinical samples were used with informed consent conforming to the ethical guidelines of the 1975 Declaration of Helsinki and study protocols were approved by the West of Scotland Research Ethics Committee. Blood samples were obtained from a cohort of patients with chronic hepatitis C and healthy volunteers (Table[1](#tbl1){ref-type="table"}). Exclusion criteria included co-infection with other viruses (hepatitis B virus or HIV), non-HCV related liver disease, active antiviral therapy, metabolic disorders, medication affecting lipid metabolism, current intravenous drug use, chronic alcohol use and a body mass index (BMI) \>30. Participants were assessed for HCV risk factors, HCV infection status (anti-HCV antibodies, viral load and virus genotype) and markers of hepatic inflammation/cirrhosis (alanine aminotransferase levels and transient elastography \[FibroScan\]). Participants were classified as having no/minimal fibrosis (FibroScan score \<7.1 kPa), fibrosis (FibroScan score 7.1--12.5 kPa) or cirrhosis (FibroScan score \>12.5 kPa) \[[@b15]\]. Statistical significance was calculated using GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA).

###### 

Clinical data

                                                                  Healthy controls    Genotype 1                                            Genotype 3
  --------------------------------------------------------------- ------------------- ----------------------------------------------------- --------------------------------------------------------------------------------
  *n*                                                             15                  22                                                    22
  Male:Female                                                     10:5                15:7                                                  19:3
  Caucasian:Asian                                                 15:0                22:0                                                  19:3
  Age                                                             44.0 (37.1--50.9)   45.1 (42.5--47.7)                                     40.6 (37.7--43.6)
  BMI[\*](#tf1-1){ref-type="table-fn"}                            25.2 (23.2--27.1)   25.4 (24.3--26.6)                                     25.1 (23.5--26.7)
  rs12979860 (CC:CT:TT)                                           n/d                 5:14:3                                                6:8:2[†](#tf1-2){ref-type="table-fn"}
  Previous Treatment Failure (Y:N)                                n/a                 11:11                                                 4:18
  Viral Load (1 × 10^6^ IU/mL)[\*](#tf1-1){ref-type="table-fn"}   n/a                 1.5 (0.7--2.2)                                        2.1 (0.6--3.6)
  FibroScan (kPA)                                                 n/d                 13.7 (6.4--21.1)                                      14.6 (7.3--21.9)
  Serum ALT (IU/mL)                                               33.5 (23.6--43.4)   110.6 (41.6--179.6)[‡](#tf1-3){ref-type="table-fn"}   127.7 (46.0--209.5)[‡](#tf1-3){ref-type="table-fn"}
  Serum Cholesterol (mmol/L)                                      5.4 (5.0--5.8)      5.0 (4.6--5.4)                                        3.9 (3.4--4.4)[‡](#tf1-3){ref-type="table-fn"}[§](#tf1-4){ref-type="table-fn"}
  Serum Total/HDL Cholesterol                                     4.6 (3.9--5.2)      3.8 (3.3--4.3)                                        3.9 (3.2--4.6)
  Haemoglobin (g/L)                                               146 (135--157)      150 (143--156)                                        150 (140--159)
  Platelets (1 × 10^9^/L)                                         265 (216--313)      232 (186--278)                                        189 (162--217)[‡](#tf1-3){ref-type="table-fn"}
  White Cell Count (1 × 10^9^/L)                                  6.6 (6.0--7.3)      6.4 (5.6--7.2)                                        6.7 (5.8--7.5)
  Lymphocytes (1 × 10^9^/L)                                       2.0 (1.8--2.3)      2.2 (1.8--2.6)                                        2.1 (1.8--2.4)
  Neutrophils (1 × 10^9^/L)                                       3.9 (3.3--4.4)      3.5 (2.9--4.0)                                        3.9 (3.2--4.5)

All values are given as the mean with the 95% confidence interval in brackets with n/a signifying not applicable and n/d signifying not done.

For viral load *n *=* *41 (22 gt1 and 21 gt3); for BMI *n *=* *57 (15 healthy control, 21 gt1 and 21 gt3).

Genotype information was unavailable for six gt3-infected patients. Significant differences (*P*-value\<0.05) are denoted as

versus the 'Healthy Control' group or

versus the 'Genotype 1' group.

RNA extraction
--------------

RNA was extracted from PBMCs following separation over a density gradient (Histopaque®-1077; Sigma-Aldrich, Gillingham, UK). Total RNA was extracted using RNeasy Minicolumns with on-column DNase-digestion (Qiagen, Manchester, UK) following manufacturer\'s guidelines. RNA quality and quantity were assessed by NanoDrop 1000 (Thermo Scientific) (Thermo Fisher Scientific, Waltham, MA, USA) and 2200 TapeStation (Agilent Technologies, Santa Clara, CA, USA) instruments.

Microarray analysis
-------------------

RNA (150 ng) was hybridized onto modified Agilent 4 × 44K microarrays containing 201 additional probes, corresponding to 119 genes previously not found on the array (Agilent Technologies, Santa Clara, CA, USA). Raw data were extracted using Feature Extraction software (Agilent Technologies, Santa Clara, CA, USA), and the generated text files were processed and analysed with ChipInspector (Genomatix Software, Munich, Germany). Differentially regulated genes were selected with a cut-off fold change of 2 (in either direction) and a signal intensity of \>100 in one of the biological groups.

Clustering and gene-annotation enrichment analysis
--------------------------------------------------

Gene-annotation enrichment analysis was carried out with DAVID Bioinformatics Resource 6.7 \[[@b16]\], using the Agilent HumanGenomeCGH44K background gene set (for microarray data), and adjusting for multiple testing by the Benjamini--Hochberg procedure. Data were clustered in R using the log-transformed microarray signal values with the hclust package (utilizing agglomerative clustering) and visualized by heatmap.2 (from the gplots package).

Reverse transcription and quantitative real-time PCR (Q-PCR)
------------------------------------------------------------

Total RNA was reverse transcribed with the SuperScript® VILO™ cDNA Synthesis kit (Life Technologies, Paisley, UK) according to manufacturer\'s instructions. Microarray results were validated by Q-PCR using TaqMan® assays (Life Technologies, Paisley, UK; Table S1). *HPRT1* was used as a reference gene, and data were analysed using the comparative threshold cycle method \[[@b17]\]. Statistical significance was calculated using the nonparametric Kruskal--Wallis test with Dunn\'s multiple comparison post-test using GraphPad Prism 5.

Results
=======

Genotype-specific transcriptional changes are observed in known ISGs but not genes related to lipid metabolism
--------------------------------------------------------------------------------------------------------------

To investigate potential genotype-specific differences in PBMC transcription, we selected a subgroup of chronically infected patients (gt1 *n *=* *8 and gt3 *n *=* *8) who were matched by age, gender and had low FibroScan scores (to exclude any transcriptional changes associated with fibrosis or cirrhosis). We utilized Agilent 4 × 44K microarrays modified to detect additional genes, involved in lipid metabolic processes that are absent in the original array. A total of 42 differentially expressed genes were identified; 37 were up-regulated in the gt1 samples and 5 were up-regulated in the gt3 samples (Fig.[1](#fig01){ref-type="fig"} and Table S2). This small number of differentially expressed genes highlights the subtle difference between chronic infection with either HCV gt1 or gt3. Sample clustering on the basis of the log-transformed microarray signal values from these 42 differentially regulated genes failed to separate the different genotypes although a subgroup of gt1-infected samples did form a distinct cluster (Fig.[1](#fig01){ref-type="fig"}). This cluster was statistically significant when analysed by multiscale bootstrap resampling (data not shown). This implies that at least a proportion of patients infected with gt1 HCV are characterized by a distinct peripheral transcriptional profile.

![Heat map of genes identified as differentially expressed between gt1- (*n *=* *8; blue labels) and gt3-infected patients (*n *=* *8; red labels). Microarray signal values were log-transformed, scaled using *Z*-score (dark blue denotes higher and dark red denotes lower), and then clustered based on Euclidean distance metrics using the hclust R package.](jvh0022-0384-f1){#fig01}

The majority of the differentially expressed genes are known ISGs and play important roles in pro-inflammatory immune responses to viral infections. The largest differential transcription was observed for interferon alpha-inducible protein 27 (IFI27; up-regulated 6.0-fold in HCV gt1 infection; Table S2). Sarasin-Filipowicz and colleagues previously identified genotype-specific transcription of IFI27 in liver biopsies \[[@b18]\]; however, reports are conflicting on whether IFI27 transcription is also up-regulated in PBMC samples from patients with chronic HCV infection \[[@b13],[@b14]\]. No genes relating to lipid metabolism were identified as differentially expressed between HCV gt1 and gt3 infection, and only one gene related to lipid signalling was identified -- free fatty acid receptor 2 (FFAR2; up-regulated 2.2-fold in HCV gt1 infection; Table S2), a G-protein-coupled receptor, expressed on leucocytes, that recognizes short-chain free fatty acids \[[@b19]\].

Enrichment of immune-related pathways and Type I IFN-responsive genes in gt1-infected patients
----------------------------------------------------------------------------------------------

To gain further functional understanding of these genotype-specific differences, we performed gene-annotation enrichment analysis. Significant enrichment of gene terms relating to antiviral pathways and innate immune responses were identified amongst the 42 differentially transcribed genes (Fig.[2](#fig02){ref-type="fig"}a). In particular, the gt1-infected patients demonstrated an enrichment of the immune response pathway, the inflammatory response pathway and the antiviral interferon-induced 56K protein family \[[@b20]\] (Fig.[2](#fig02){ref-type="fig"}a). Although decreased peripheral cholesterol levels were observed in the gt3-infected patients (Table[1](#tbl1){ref-type="table"}), no enrichment of lipid or cholesterol metabolic pathways was observed.

![Pathway analysis of the differentially expressed genes identified from microarray analysis (gt1, *n *=* *8; gt3, *n *=* *8). (a) Enriched terms from DAVID analysis ranked by corrected *P*-value. (b) Classification of identified IFN-stimulated genes using published sets of genes induced by Type I IFN, Type II IFN or TNF*α* in PBMC \[[@b21]\].](jvh0022-0384-f2){#fig02}

To further analyse these differentially transcribed genes, we matched the ISGs to published gene sets generated following stimulation of PBMCs with Type I IFN, Type II IFN, interleukin (IL)12 or TNF*α*, respectively \[[@b21]\]. The ISGs identified as having genotype-specific expression were all classified as being induced by Type I IFN, and genes induced exclusively by Type II IFN or TNF*α* were absent (Fig.[2](#fig02){ref-type="fig"}b).

Patients infected with HCV gt1 have elevated peripheral ISG transcription but comparable IFN transcription to gt3-infected patients
-----------------------------------------------------------------------------------------------------------------------------------

To validate the microarray findings, we selected three of the identified genotype-specific genes (interferon-induced protein with tetratricopeptide repeats 1 (*IFIT1*), ISG15 ubiquitin-like modifier (*ISG15*) and radical S-adenosyl methionine domain containing 2 (*RSAD2*)) and analysed their expression by Q-PCR in the full cohort of patients chronically infected with either HCV gt1 (*n *=* *22) or gt3 (*n *=* *22). We also analysed a group of age- and gender-matched uninfected controls (*n *=* *15). The infected patients showed no significant differences in viral load, liver function tests or FibroScan scores. Gt3 infection was associated with significantly reduced serum cholesterol compared to the uninfected controls and gt1 infection, consistent with previous studies \[[@b7]--[@b10]\], as well as a significantly reduced platelet count compared to the uninfected controls (Table[1](#tbl1){ref-type="table"}).

We detected a statistically significant increase in transcription of *IFIT1*,*ISG15* and *RSAD2* in gt1-infected patients compared to healthy controls, which was absent or reduced in gt3-infected patients (Fig.[3](#fig03){ref-type="fig"}). This elevated transcription of ISGs in gt1-infected patients (geometric mean fold change vs healthy controls: *IFIT1 *=* *2.50, *ISG15 *=* *2.55 and *RSAD2 *=* *2.46) validates the microarray results and demonstrates an association between HCV gt1 and elevated transcription of pro-inflammatory ISGs in the periphery.

![Validation of microarray results and transcription of IFNs using Q-PCR in gt1- (*n *=* *22) and gt3-infected patients (*n *=* *22), and healthy controls (*n *=* *15). For *IFNA2 n *=* *17 gt1, 19 gt3 and 11 healthy controls; for *IFNB1 n *=* *10 gt1, 10 gt3 and six healthy controls; and for *IFNL2 n *=* *8 gt1, 10 gt3 and eight healthy controls. Plots show geometric mean with 95% confidence interval. \*denotes *P*-value \<0.05 and \*\*\*denotes *P*-value \<0.001.](jvh0022-0384-f3){#fig03}

To explore the possibility that elevated expression of IFNs in PBMCs induces the ISGs in chronically infected patients, we profiled the transcription of the Type I IFNs *IFNA2* and *IFNB1*, the Type II IFN *IFNG*, and the Type III IFN *IFNL2*. No significant differences were observed in the transcription levels of any of the IFNs between the three groups (Fig.[3](#fig03){ref-type="fig"}). The transcription of both Type I and Type III IFNs were very low across all groups, and indeed transcription was undetectable in a number of samples, suggesting that IFNs are unlikely to be driving the elevated ISG transcription in gt1-infected patients.

Genotype-specific transcriptional profiles are independent of previous treatment failure and unfavourable IL28B genotype
------------------------------------------------------------------------------------------------------------------------

Previous studies have identified elevated ISG expression in the liver \[[@b18],[@b22]\] and PBMCs \[[@b23]\] as predictors of response to IFN outcome. This elevated ISG expression is also associated with the unfavourable *IL28B* 'CT' and 'TT' genotypes \[[@b24]\]. We therefore sought to examine whether the differences we observed between gt1 and gt3 infections were simply due to differences in the number of individuals with previous treatment failure or in the balance of *IL28B* genotypes.

The number of patients who had previously failed IFN-based therapy was larger in the gt1-infected group compared to the gt3-infected group (11 *vs* 4; *P*-value = 0.055), as was expected based on the genotypic differences in treatment response rates. Despite this, the transcription levels of *IFIT1*,*ISG15* and *RSAD2* between previous treatment failures *vs* treatment naïve individuals were similar (Fig.[4](#fig04){ref-type="fig"}a). The gt1- and gt3-infected patient groups had similar proportions of individuals with favourable 'CC' and unfavourable 'CT/TT' genotypes (Table[1](#tbl1){ref-type="table"}). No differences in the transcription levels of *IFIT1*,*ISG15* and *RSAD2* were observed between individuals with favourable or unfavourable *IL28B* genotypes (Fig.[4](#fig04){ref-type="fig"}b). These results imply that HCV gt1 may influence peripheral immune cells and induce elevated ISG transcription independent of the described effects of treatment response phenotype or *IL28B* genotype.

![Transcription of genotype-specific genes *IFIT1*,*ISG15* and *RSAD2*. (a) Impact of previous treatment failure comparing treatment naive patients (*n *=* *29) and patients who have previously failed IFN-based therapy (*n *=* *15). (b) Impact of *IL28B* genotype comparing patients with the favourable 'CC' genotype (*n *=* *11) and patients with the unfavourable 'CT/TT' genotypes (*n *=* *27). Plots show geometric mean with 95% confidence interval.](jvh0022-0384-f4){#fig04}

Discussion
==========

Profiling the transcriptional changes in PBMCs associated with specific HCV genotypes illuminates genotype-specific host--pathogen interactions underlying the known clinical features of chronic HCV infection associated with particular genotypes. Using a group of age- and gender-matched patients, selected on the basis of low FibroScan scores to minimize any changes associated with fibrosis or cirrhosis, we identified distinct changes in ISG and immune-related gene transcription within PBMCs from patients infected with either HCV gt1 or gt3. Chronic infection with HCV gt1 was associated with elevated transcription of genes induced by Type I IFNs and involved in immune response and inflammatory response pathways.

Our results confirm previous studies that have identified the presence of ongoing proinflammatory gene induction in PBMCs from patients with chronic HCV infection \[[@b13],[@b14]\]. Furthermore, our results demonstrate that this proinflammatory induction is exaggerated in patients infected with HCV gt1. Importantly, the elevated transcription we observed is unrelated to differences in the proportion of individuals with 'favourable' or 'unfavourable' *IL28B* genotype or the proportion of patients who have previously failed IFN-based therapy, both of which are associated with elevated expression of ISGs \[[@b25]\].

The ISGs identified in our study with elevated transcriptional in PBMCs from patients with gt1 infection include a number of genes that have previously been identified in transcriptomic studies of HCV-infected liver biopsies \[[@b18],[@b22],[@b25],[@b26]\]. These studies compared liver transcriptomes between patients who achieved SVR with patients who failed to respond to IFN-based therapies and demonstrated that higher expression of ISGs is associated with poor response to therapy \[[@b18],[@b22],[@b25],[@b26]\]. Indeed, pre-existing induction of ISGs predicts treatment response with greater accuracy than the widely used *IL28B* genotype \[[@b25]\]. While these studies failed to specifically address genotype-specific transcriptional changes within the liver, when treatment response was excluded, viral genotype had the next biggest influence on differential gene transcription \[[@b22]\].

In the liver, the elevated transcription of ISGs includes a number of negative regulators of IFN*α* signalling pathways, such as ubiquitin-specific peptidase 18 (*USP18*), which inhibits further IFN signalling and is thought to contribute to the lack of IFN*α*-induced gene induction in treatment nonresponders \[[@b27],[@b28]\]. Strong IFN responses have also been hypothesized to limit the development of robust T-cell immune responses during the establishment of chronic HCV infection \[[@b29]\]. Our results suggest that a general elevation of PBMC ISG transcription occurs in gt1-infected patients. This is in agreement with the conclusion by Sarasin-Filipowicz and colleagues that patients infected with HCV gt1 more frequently have increased expression of ISGs in the liver, which provides a plausible explanation for the relatively poor response to IFN-based therapies in these patients \[[@b18]\]. It is perhaps noteworthy that gt1 infection is associated with spontaneous viral clearance during acute infection \[[@b30]\]. The strong pro-inflammatory responses induced by HCV gt1 may aid clearance during early acute infection but hinder IFN signalling once chronic infection is established.

Despite observing a significant level of hypocholesterolemia in gt3-infected patients, we did not observe changes in genes involved in lipid metabolism. While *in vitro* studies have identified alterations in metabolic gene expression induced by HCV gt3 proteins \[[@b31],[@b32]\], our results demonstrate that such transcriptional changes are not apparent in PBMCs. It is possible that changes in lipid metabolism may only occur within liver hepatocytes despite systemic reduction in total cholesterol levels. Alternatively, genotype-specific differences in lipid metabolism may only be evident at a post-transcriptional level. Clark and colleagues have previously identified a gt3-specific decrease in the serum levels of metabolites involved in the late stages of cholesterol synthesis, which resolve upon successful response to therapy, indicating that HCV gt3 is able to directly perturb cholesterol biosynthesis at a post-transcriptional level \[[@b33]\].

While the elevation of ISG transcription is evident in PBMC samples from gt1-infected patients, the mechanisms underlying this induction are not understood. A key question raised from our study is why gt1 and gt3 mediate different transcriptional responses? Although it is likely that reduced peripheral cholesterol levels act to reduce pro-inflammatory responses of peripheral immune cells, as described previously \[[@b11],[@b12]\], this fails to explain potential genotype-specific differences observed in transcriptomic studies of the liver \[[@b18],[@b22]\]. No differences in the transcription of Type I, II, or III IFNs were observed between any of the study groups, suggesting that alternative immune signalling pathways drive the induction of ISGs. Future studies should address whether gt1- or gt3-specific genetic sequences are responsible for driving elevated ISG transcription.

In summary, our data are consistent with the hypothesis that gt1 infection drives a skewed Type I IFN response. These transcriptional differences may shed light on possible mechanisms underlying the distinctive clinical manifestations of these two HCV genotypes. Our study lays the foundation for further analysis of dysregulation of host cell factors by the distinct HCV genotypes.
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**Table S1.**Gene selection for Q-PCR assays.

**Table S2.** Genes differentially expressed in gt1-version gt3-infected patients.
